Cresco Labs (CRLBF) Receivables - Net (2019 - 2026)

Cresco Labs' (CRLBF) quarterly Receivables - Net came in at $38.1 million in Q1 2026, up 0.69% on a QoQ basis from $37.9 million in Q4 2025.

Cresco Labs (CRLBF) Receivables - Net (2019 - 2026) Analysis & Trends

Cresco Labs (CRLBF) has 8 years of Receivables - Net data on file, last reported at $38.1 million in Q1 2026.

Quarterly Receivables - Net changed N/A year-over-year to $38.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.1 million (changed N/A YoY) and the FY2025 annual result came in at $37.9 million, changed N/A from the prior year.
Receivables - Net improved to $38.1 million in Q1 2026, from $37.9 million in the prior quarter.
In the past five years, Receivables - Net ranged from a high of $59.0 million in Q4 2023 to a low of $37.9 million in Q4 2025.
A 5-year average of $48.9 million and a median of $49.8 million in 2024 frame the typical range for Receivables - Net.
The widest YoY moves for Receivables - Net: up 34.25% in 2022, down 34.25% in 2022.
Tracing CRLBF's Receivables - Net over 5 years: stood at $48.7 million in 2022, then increased by 21.24% to $59.0 million in 2023, then fell by 7.58% to $54.6 million in 2024, then sank by 30.56% to $37.9 million in 2025, then climbed by 0.69% to $38.1 million in 2026.
The last three Receivables - Net figures came in at $38.1 million (Q1 2026), $37.9 million (Q4 2025), and $54.6 million (Q3 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.94 Bn	42.97 Bn	-
2	Teva Pharmaceutical Industries	43.08 Bn	39.43 Bn	2.15 Bn
3	Zoetis	31.54 Bn	29.87 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.60 Bn	22.80 Bn	5.10 Bn
5	United Therapeutics	22.12 Bn	19.46 Bn	683.80 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn
8	Elanco Animal Health	11.69 Bn	11.16 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.13 Bn	9.96 Bn	-
10	Cresco Labs	292.94 Mn	228.83 Mn	86.95 Mn

Download Data